Following the declaration of a Sudan Ebolavirus outbreak in the Republic of Uganda on September 20, 2022, the outbreak has now spread to seven districts (Kasanda, Kyegegwa, Bunyangabu, and Kagadi districts beyond the original epicenter in Mubende district, and then to Kampala City and Wakiso.
As of November 4, 2022, media reports indicated there had been 152 confirmed Sudan Ebolavirus (SUDV) cases and 69 related fatalities.
Uganda’s response activated the WHO Incident Management System on November 3, 2022, to help control the outbreak.
Vaccination is usually one of the response interventions in such an outbreak.
However, there are currently no licensed vaccines (or therapeutics) for Ebola disease caused by the SUDV.
But several candidate vaccines appear to be suitable for evaluation in human clinical trials.
The SUDV vaccine developers and funders who will make the candidate vaccines available include the University of Oxford and the Serum Institute of India, the Sabin Vaccine Institute, the U.S. Biomedical Advanced Research and Development Authority, and the NIH, as well as the International AIDS Vaccine Initiative and Merck.
Moreover, to notify travelers of their potential health risks, the U.S. CDC Alert – Level 2, Practice Enhanced Precautions, regarding Uganda’s SUDV outbreak remains in effect as of November 4, 2022.
Source link : https://news.google.com/__i/rss/rd/articles/CBMiWWh0dHBzOi8vd3d3LnZheGJlZm9yZXRyYXZlbC5jb20vMjAyMi8xMS8wNC9zdWRhbi1lYm9sYXZpcnVzLXZhY2NpbmUtY2FuZGlkYXRlcy1pZGVudGlmaWVk0gFdaHR0cHM6Ly93d3cudmF4YmVmb3JldHJhdmVsLmNvbS8yMDIyLzExLzA0L3N1ZGFuLWVib2xhdmlydXMtdmFjY2luZS1jYW5kaWRhdGVzLWlkZW50aWZpZWQ_YW1w?oc=5
Publish date : 2022-11-04 15:54:16